Redefining genetics

Democratizing the efficient use of NGS (next generation sequencing) in liquid biopsies for cancer diagnostics and beyond

Augmenting cancer care

Genomill is developing and enabling accessible top-tier cancer diagnostics. We are driving a global impact on healthcare with our unique technological innovation – Geno1™.

Reduced
cost

Increased
accuracy

Faster
turn-around-time

Geno1™

Driven by world-class research

Our Geno1™ technology is a unique combination of molecular biology, robotics, next-generation DNA sequencing and artificial intelligence.

It truly provides means for unprecedented scaling of liquid biopsies and beyond by tackling the three main drivers: cost, accuracy and turn-around-time.

Join our journey

We’re set to saturate the scattered liquid biopsy space with our technology. We offer Geno1™ for out-licensing and are continuously looking for new long-term partnerships.

Join us in democratizing true game-changing technology!

Get in touch by emailing us at info@genomill.com!

Latest news

<font color="#57C1AC"> Genomeweb: </font> Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing

Genomeweb: Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing

 NEW YORK – After closing an investment round last month for an undisclosed sum, Finnish firm Genomill Health is aiming to broaden adoption of its Geno1 technology, a barcoding-based method that it believes can enhance sequencing accuracy and lower costs…
Genomill Health closes investment round to expand beta-testing with liquid biopsy players

Genomill Health closes investment round to expand beta-testing with liquid biopsy players

Genomill Health closes a financing round led by a deep tech VC Voima Ventures to expand its novel and disruptive technology, focusing on efficient use of NGS (next generation sequencing) in liquid biopsies for cancer diagnostics.